Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. - Pi-Sunyer FX; Aronne LJ; Heshmati HM; Devin J; Rosenstock J (JAMA, 2006)